Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2020-10-27 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
关于公司变更会计估计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shanghai Medicilon Inc. regarding a change in accounting estimates related to the depreciation period of fixed assets (buildings). It details the reasons for the change, the approval by the board and supervisory committee, and includes opinions from independent directors and auditors. The document does not contain full financial statements or comprehensive financial performance data but rather focuses on a specific accounting policy change and its impact. It is a regulatory announcement about an accounting estimate change, not a full annual or interim report, audit report, or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-10-27 Chinese
2020年限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled as an implementation and assessment management method for a 2020 restricted stock incentive plan by Shanghai Medicilon Inc. It details the purpose, principles, scope, assessment institutions, performance indicators, procedures, and management of the stock incentive plan. The content focuses on governance and management of an equity incentive plan rather than financial results, audit, or regulatory announcements. It is a governance-related document outlining internal rules and procedures for stock incentives, which aligns with governance information filings. The document length is 3231 characters, which is relatively short but contains substantive content about governance practices rather than being a mere announcement or certification. Therefore, the most appropriate classification is Governance Information (CGR).
2020-10-27 Chinese
上海信公轶禾企业管理咨询有限公司关于上海美迪西生物医药股份有限公司2020年限制性股票激励计划（草案）之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report regarding a 2020 Restricted Stock Incentive Plan for Shanghai Medicilon Inc. It includes detailed analysis of the stock incentive plan, its compliance with laws and regulations, financial impact, accounting treatment, and feasibility. The document is lengthy (15,000 characters) and contains substantive financial and operational details about the incentive plan, not just an announcement or summary. It is not an annual report, earnings release, or management discussion but a specialized advisory report on a stock incentive plan. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through stock incentives. Therefore, the classification is CAP with high confidence.
2020-10-27 Chinese
2020年第三季度报告正文
Interim / Quarterly Report Classification · 98% confidence The document is titled '2020 年第三季度报告正文' which translates to '2020 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of significant changes in financial metrics for the third quarter of 2020. The document also includes management assurances about the accuracy and completeness of the report, and it explicitly states that the report is unaudited. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarterly) confirms that this is an Interim / Quarterly Report. The document length (9088 characters) and content depth support this classification rather than a brief announcement or a regulatory filing. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). Q3 2020
2020-10-27 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司首次公开发行部分限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from a sponsoring securities company regarding the listing and circulation of restricted shares following the initial public offering (IPO) of Shanghai Medicilon Inc. It details the types and quantities of restricted shares becoming tradable after the lock-up period, shareholder commitments, and compliance with relevant laws and regulations. The document does not contain financial statements or earnings data, nor is it an announcement of voting results or management changes. It is a regulatory compliance and verification report related to share circulation post-IPO. This type of document fits best under Regulatory Filings (RNS) as it is a compliance and verification statement rather than a financial report or announcement of a report.
2020-10-27 Chinese
2020年限制性股票激励计划（草案）
Remuneration Information Classification · 95% confidence The document is titled '上海美迪西生物医药股份有限公司 2020 年限制性股票激励计划（草案）' which translates to 'Shanghai Medicilon Biopharmaceutical Co., Ltd. 2020 Restricted Stock Incentive Plan (Draft)'. It is a detailed draft plan for a restricted stock incentive program, including legal references, definitions, objectives, management structure, eligibility, stock quantities, vesting conditions, performance targets, and adjustment methods. The document is comprehensive and lengthy (15,000 characters), containing no financial statements or earnings data but focusing on stock incentive plan details. This type of document is related to executive and employee compensation and stock incentive arrangements, which falls under Remuneration Information filings. It is not an announcement, certification, or a general regulatory filing, but a detailed plan document. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2020-10-27 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.